SummitTX Capital’s Oric Pharmaceuticals ORIC Stock Holding History

SummitTX Capital’s Portfolio ORIC Stock Details ORIC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-42,446	Closed	-$538K	–	957
2026 Q1	$538K	Buy	+42,446	New	+$482K	0.02%	555

Other funds holding ORIC

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

SOCM

SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return

VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

SummitTX Capital's ORIC Position: Q2 2026 in Review

SummitTX Capital sold out of Oric Pharmaceuticals (ORIC) in Q2 2026, closing a stake of 42,446 shares — an estimated $538K sold.

SummitTX Capital first reported a position in ORIC in Q1 2026 and held it in 1 quarter. The position peaked at $538K in Q1 2026. 181 funds tracked by Wall St. Rank hold ORIC as of Q2 2026.

SummitTX Capital reported no remaining Oric Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
SummitTX Capital sold 42,446 Oric Pharmaceuticals shares in Q2 2026, an estimated $538K.
SummitTX Capital first reported a position in Oric Pharmaceuticals in Q1 2026 and held it in 1 quarter.
SummitTX Capital's Oric Pharmaceuticals position peaked at $538K in Q1 2026.
181 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q2 2026.

Based on SummitTX Capital's 13F filing for Q2 2026, filed 14 Aug 2026.